SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: quidditch who wrote (207)4/8/2002 5:44:51 PM
From: IRWIN JAMES FRANKEL  Read Replies (1) of 508
 
<Seems as though the Rochester Mayo Clinic hasn't found anything it likes in the anti-fibrotic drugs (a few weeks ago, someone posted a very negative interpretation from some RMC investigators who had reviewed the ITMN study of the effects of actimmune in ipf in a 19-patient trial).>

I don't want to be picky but this statement is not correct. The RMC work was a meta-study in which they looked at the records of patients who had been treated at Mayo. I do not think that it was in any way a "review" of an ITMN study. It did cast a shadow on the favorable data that is coming out.

ij
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News